ArticleJournal of advanced research2026
A rapidly fabricated bone marrow enrichment material with a controllable pore size promotes osteogenesis close to autogenous bone graft in clinic.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cation-surface RADA16-based self-assembling peptide hydrogel with high adhesion and osteogenesis promoting bone regeneration.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe shortage of highly osteogenic grafts significantly impacts clinical bone repair and reconstruction in clinic. Selective cell retention technology increases the number of bone marrow (BM)-derived osteogenic cells on scaffold materials. A suitable pore size is key for improving the efficiency of BM cell enrichment of scaffold materials. Many materials with a controllable pore size have been developed, but due to ethics policies, only a few have been approved for clinical use.
objectivesIn this study, cortical bone shavings with a small pore size were mixed in different ratios with decalcified bone matrix, which has a relatively larger pore size, to form a new BM enrichment scaffold material with an adjustable pore size (MIX materials).
methodsWe evaluated the in vitro and in vivo enrichment efficiency and osteogenic ability of materials with different pore sizes.
resultsMIX material (1:1) had suitable pore size that was beneficial for the effective enrichment of BM-derived cells and cytokines and promoted the proliferation and osteogenic differentiation of mesenchymal stem cells in vitro. A subcutaneous heterotopic transplantation experiment in a nude mouse model confirmed that MIX material enhanced osteoinductive potential and angiogenesis in vivo. Similarly, a large animal model using goats with a critical bone defect (2.5 cm) showed that the osteogenic ability of enriched MIX was superior to that of nonenriched MIX after 3 months. A subsequent self-controlled prospective clinical study demonstrated that the osteogenic ability of enriched MIX material was close to that of an autograft (the clinical gold standard) in lumbar intervertebral fusion surgery.
conclusionMIX scaffold material is an effective choice for the clinical treatment of bone repair and bone reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.